Longitudinal analysis of endurance and respiratory function from a natural history study of Morquio A syndrome

Molecular Genetics and Metabolism

Volumn 114, Issue 2, 2015, Pages 186-194

  Harmatz, Paul R ^a   Mengel, Karl Eugen ^b   Giugliani, Roberto ^c   Valayannopoulos, Vassili ^d   Lin, Shuan Pei ^e   Parini, Rossella ^f   Guffon, Nathalie ^g   Burton, Barbara K ^h   Hendriksz, Christian J ⁱ   Mitchell, John J ^j   Martins, Ana Maria ^k   Jones, Simon A ^l   Guelbert, Norberto ^m   Vellodi, Ashok ⁿ   Wijburg, Frits A ^o   Yang, Ke ^p   Slasor, Peter ^p   Decker, Celeste ^p  

^a CHILDREN S HOSPITAL OAKLAND   (United States)

^b JOHANNES GUTENBERG UNIVERSITY   (Germany)

^c HOSPITAL DE CLÍNICAS DE PORTO ALEGRE   (Brazil)

^d HÔPITAL NECKER ENFANTS MALADES   (France)

^e MACKAY MEMORIAL HOSPITAL   (Taiwan)

^f SAN GERARDO HOSPITAL   (Italy)

^g HOSPICES CIVILS DE LYON   (France)

^h NORTHWESTERN UNIVERSITY   (United States)

ⁱ BIRMINGHAM CHILDREN S HOSPITAL NHS FOUNDATION TRUST   (United Kingdom)

^j MCGILL UNIVERSITY HEALTH CENTRE   (Canada)

^k FEDERAL UNIVERSITY OF SÃO PAULO   (Brazil)

^l UNIVERSITY OF MANCHESTER   (United Kingdom)

^m Hospital de Ninos de Cordoba   (Argentina)

ⁿ GREAT ORMOND STREET HOSPITAL   (United Kingdom)

^o ACADEMIC MEDICAL CENTER   (Netherlands)

^p BIOMARIN PHARMACEUTICAL INC   (United States)

more..

Author keywords

6minute walk test; Endurance; Longitudinal analysis; Morquio A; MPS IVA; Mucopolysaccharidosis IVA

Indexed keywords

ELOSULFASE ALFA;

3 MINUTE STAIR CLIMB TEST; 6 MINUTE WALK TEST; ADOLESCENT; ADULT; ARTICLE; BONE DYSPLASIA; CHILD; CONTROLLED STUDY; DYSPNEA; ENDURANCE; EXPERIMENTAL LOCOMOTOR ACTIVITY TEST; FATIGUE; FEMALE; FOLLOW UP; FORCED VITAL CAPACITY; HISTORY; HUMAN; INFANT; LUNG FUNCTION; MAJOR CLINICAL STUDY; MALE; MAXIMUM VOLUNTARY VENTILATION; MORQUIO A SYNDROME; MORQUIO SYNDROME; NEWBORN; PRIORITY JOURNAL; RESPIRATORY FUNCTION; RESPIRATORY TRACT PARAMETERS; SHORT STATURE; WALKING AID; BREATHING; CLINICAL TRIAL; FORCED EXPIRATORY VOLUME; LONGITUDINAL STUDY; LUNG VENTILATION; MIDDLE AGED; MOTOR ACTIVITY; MULTICENTER STUDY; PATHOPHYSIOLOGY; PRESCHOOL CHILD; YOUNG ADULT;

ADOLESCENT; ADULT; CHILD; CHILD, PRESCHOOL; FEMALE; FORCED EXPIRATORY VOLUME; HUMANS; INFANT; LONGITUDINAL STUDIES; MALE; MAXIMAL VOLUNTARY VENTILATION; MIDDLE AGED; MOTOR ACTIVITY; MUCOPOLYSACCHARIDOSIS IV; PHYSICAL ENDURANCE; RESPIRATION; YOUNG ADULT;

EID: 84921759170     PISSN: 10967192     EISSN: 10967206     Source Type: Journal    
DOI: 10.1016/j.ymgme.2014.10.015     Document Type: Article

References (36)

1. Montano A.M., Tomatsu S., Gottesman G.S., Smith M., Orii T. International Morquio A registry: clinical manifestation and natural course of Morquio A disease. J. Inherit. Metab. Dis. 2007, 30:165-174.
2. Harmatz P., Mengel K.E., Giugliani R., Valayannopoulos V., Lin S.P., Parini R., Guffon N., Burton B.K., Hendriksz C.J., Mitchell J., Martins A., Jones S., Guelbert N., Vellodi A., Hollak C., Slasor P., Decker C. The Morquio A clinical assessment program: baseline results illustrating progressive, multisystemic clinical impairments in Morquio A subjects. Mol. Genet. Metab. 2013, 109:54-61.
3. Hendriksz C.J., Al-Jawad M., Berger K.I., Hawley S.M., Lawrence R., Mc Ardle C., Summers C.G., Wright E., Braunlin E. Clinical overview and treatment options for non-skeletal manifestations of mucopolysaccharidosis type IVA. J. Inherit. Metab. Dis. 2013, 36:309-322.
4. Tomatsu S., Montano A.M., Oikawa H., Smith M., Barrera L., Chinen Y., Thacker M.M., Mackenzie W.G., Suzuki Y., Orii T. Mucopolysaccharidosis type IVA (Morquio A disease): clinical review and current treatment. Curr. Pharm. Biotechnol. 2011, 12:931-945.
5. Hendriksz C.J., Harmatz P., Beck M., Jones S., Wood T., Lachman R., Gravance C.G., Orii T., Tomatsu S. Review of clinical presentation and diagnosis of mucopolysaccharidosis IVA. Mol. Genet. Metab. 2013, 110:54-64.
6. Solanki G.A., Martin K.W., Theroux M.C., Lampe C., White K.K., Shediac R., Lampe C.G., Beck M., Mackenzie W.G., Hendriksz C.J., Harmatz P.R. Spinal involvement in mucopolysaccharidosis IVA (Morquio-Brailsford or Morquio A syndrome): presentation, diagnosis and management. J. Inherit. Metab. Dis. 2013, 36:339-355.
7. White K.K., Jester A., Bache C.E., Harmatz P.R., Shediac R., Thacker M.M., Mackenzie W.G. Orthopedic management of the extremities in patients with Morquio A syndrome. J. Child. Orthop. 2014, 8:295-304.
8. Tomatsu S., Montano A.M., Nishioka T., Gutierrez M.A., Pena O.M., Tranda Firescu G.G., Lopez P., Yamaguchi S., Noguchi A., Orii T. Mutation and polymorphism spectrum of the GALNS gene in mucopolysaccharidosis IVA (Morquio A). Hum. Mutat. 2005, 26:500-512.
9. Dung V.C., Tomatsu S., Montano A.M., Gottesman G., Bober M.B., Mackenzie W., Maeda M., Mitchell G.A., Suzuki Y., Orii T. Mucopolysaccharidosis IVA: correlation between genotype, phenotype and keratan sulfate levels. Mol. Genet. Metab. 2013, 110:129-138.
10. Lin H.Y., Chuang C.K., Chen M.R., Chiu P.C., Ke Y.Y., Niu D.M., Tsai F.J., Hwu W.L., Lin J.L., Lin S.P. Natural history and clinical assessment of Taiwanese patients with mucopolysaccharidosis IVA. Orphanet J. Rare Dis. 2014, 9:21.
11. Morrone A., Tylee K.L., Al-Sayed M., Brusius-Facchin A.C., Caciotti A., Church H.J., Coll M.J., Davidson K., Fietz M.J., Gort L., Hegde M., Kubaski F., Lacerda L., Laranjeira F., Leistner-Segal S., Mooney S., Pajares S., Pollard L., Ribeiro I., Wang R.Y., Miller N. Molecular testing of 163 patients with Morquio A (mucopolysaccharidosis IVA) identifies 39 novel GALNS mutations. Mol. Genet. Metab. 2014, 112:160-170.
12. Morrone A., Caciotti A., Atwood R., Davidson K., Du C., Francis-Lyon P., Harmatz P., Mealiffe M., Mooney S., Oron T., Ryles A., Zawadzki K.A., Miller N. Morquio A syndrome-associated mutations: a review of mutations in the GALNS gene and a new locus-specific database. Hum. Mutat 2014, 35:1271-1279.
13. Lavery C., Hendriksz C. Mortality in patients with Morquio syndrome A. JIMD Rep 2014.
14. VIMIZIM™ (elosulfase alfa) US Prescribing Information 2014, BioMarin Pharmaceutical Inc., Novato, CA, (Available at www.vimizim.com).
15. McDonald A., Steiner R., Kuehl K., Turbeville S. Clinical utility of endurance measures for evaluation of treatment in patients with mucopolysaccharidosis VI (Maroteaux-Lamy syndrome). J. Pediatr. Rehabil. Med. 2010, 3:119-127.
16. Wraith J.E., Clarke L.A., Beck M., Kolodny E.H., Pastores G.M., Muenzer J., Rapoport D.M., Berger K.I., Swiedler S.J., Kakkis E.D., Braakman T., Chadbourne E., Walton-Bowen K., Cox G.F. Enzyme replacement therapy for mucopolysaccharidosis I: a randomized, double-blinded, placebo-controlled, multinational study of recombinant human alpha-L-iduronidase (laronidase). J. Pediatr. 2004, 144:581-588.
17. Muenzer J., Wraith J.E., Beck M., Giugliani R., Harmatz P., Eng C.M., Vellodi A., Martin R., Ramaswami U., Gucsavas-Calikoglu M., Vijayaraghavan S., Wendt S., Puga A.C., Ulbrich B., Shinawi M., Cleary M., Piper D., Conway A.M., Kimura A. A phase II/III clinical study of enzyme replacement therapy with idursulfase in mucopolysaccharidosis II (Hunter syndrome). Genet. Med. 2006, 8:465-473.
18. Harmatz P., Whitley C.B., Waber L., Pais R., Steiner R., Plecko B., Kaplan P., Simon J., Butensky E., Hopwood J.J. Enzyme replacement therapy in mucopolysaccharidosis VI (Maroteaux-Lamy syndrome). J. Pediatr. 2004, 144:574-580.
19. Harmatz P., Giugliani R., Schwartz I., Guffon N., Teles E.L., Miranda M.C., Wraith J.E., Beck M., Arash L., Scarpa M., Yu Z.F., Wittes J., Berger K.I., Newman M.S., Lowe A.M., Kakkis E., Swiedler S.J. Enzyme replacement therapy for mucopolysaccharidosis VI: a phase 3, randomized, double-blind, placebo-controlled, multinational study of recombinant human N-acetylgalactosamine 4-sulfatase (recombinant human arylsulfatase B or rhASB) and follow-on, open-label extension study. J. Pediatr. 2006, 148:533-539.
20. Hendriksz C.J., Burton B., Fleming T.R., Harmatz P., Hughes D., Jones S.A., Lin S.-P., Mengel E., Scarpa M., Valayannopoulos V., Guigliani R., Investigators S., Slasor P., Lounsbury D., Dummer W. Efficacy and safety of enzyme replacement therapy with BMN 110 for Morquio A syndrome (mucopolysaccharidosis IVA): a phase 3 randomised placebo-controlled study 2014.
21. Harmatz P., Yu Z.F., Giugliani R., Schwartz I.V., Guffon N., Teles E.L., Miranda M.C., Wraith J.E., Beck M., Arash L., Scarpa M., Ketteridge D., Hopwood J.J., Plecko B., Steiner R., Whitley C.B., Kaplan P., Swiedler S.J., Hardy K., Berger K.I., Decker C. Enzyme replacement therapy for mucopolysaccharidosis VI: evaluation of long-term pulmonary function in patients treated with recombinant human N-acetylgalactosamine 4-sulfatase. J. Inherit. Metab. Dis. 2010, 33:51-60.
22. ATS statement: guidelines for the six-minute walk test Am. J. Respir. Crit. Care Med. 2002, 166:111-117.
23. Harmatz P., Ketteridge D., Giugliani R., Guffon N., Teles E.L., Miranda M.C., Yu Z.F., Swiedler S.J., Hopwood J.J. Direct comparison of measures of endurance, mobility, and joint function during enzyme-replacement therapy of mucopolysaccharidosis VI (Maroteaux-Lamy syndrome): results after 48weeks in a phase 2 open-label clinical study of recombinant human N-acetylgalactosamine 4-sulfatase. Pediatrics 2005, 115:e681-e689.
24. Standardization of Spirometry Update. American Thoracic Society. Am. J. Respir. Crit. Care Med. 1995, 152:1107-1136.
25. Geiger R., Strasak A., Treml B., Gasser K., Kleinsasser A., Fischer V., Geiger H., Loeckinger A., Stein J.I. Six-minute walk test in children and adolescents. J. Pediatr. 2007, 150:395-399.
26. Lammers A.E., Hislop A.A., Flynn Y., Haworth S.G. The 6-minute walk test: normal values for children of 4-11 years of age. Arch. Dis. Child. 2008, 93:464-468.
27. Li A.M., Yin J., Au J.T., So H.K., Tsang T., Wong E., Fok T.F., Ng P.C. Standard reference for the six-minute-walk test in healthy children aged 7 to 16years. Am. J. Respir. Crit. Care Med. 2007, 176:174-180.
28. Ulrich S., Hildenbrand F.F., Treder U., Fischler M., Keusch S., Speich R., Fasnacht M. Reference values for the 6-minute walk test in healthy children and adolescents in Switzerland. BMC Pulm. Med. 2013, 13:49.
29. Chetta A., Zanini A., Pisi G., Aiello M., Tzani P., Neri M., Olivieri D. Reference values for the 6-min walk test in healthy subjects 20-50 years old. Respir. Med. 2006, 100:1573-1578.
30. Swiedler S.J., Beck M., Bajbouj M., Giugliani R., Schwartz I., Harmatz P., Wraith J.E., Roberts J., Ketteridge D., Hopwood J.J., Guffon N., Sa Miranda M.C., Teles E.L., Berger K.I., Piscia-Nichols C. Threshold effect of urinary glycosaminoglycans and the walk test as indicators of disease progression in a survey of subjects with mucopolysaccharidosis VI (Maroteaux-Lamy syndrome). Am. J. Med. Genet. A 2005, 134A:144-150.
31. Hendriksz C.J., Lavery C., Coker M., Ucar S.K., Jain M., Bell L., Lampe C. Burden of disease in patients with Morquio A syndrome: results from an international patient-reported outcomes survey. Orphanet J. Rare Dis. 2014, 9:32.
32. Lin S.P., Shih S.C., Chuang C.K., Lee K.S., Chen M.R., Niu D.M., Chiu P.C., Lin S.J., Lin H.Y. Characterization of pulmonary function impairments in patients with mucopolysaccharidoses-changes with age and treatment. Pediatr. Pulmonol. 2014, 49:277-284.
33. Rosenthal M., Bain S.H., Cramer D., Helms P., Denison D., Bush A., Warner J.O. Lung function in white children aged 4 to 19years: I-spirometry. Thorax 1993, 48:794-802.
34. Hankinson J.L., Odencrantz J.R., Fedan K.B. Spirometric reference values from a sample of the general U.S. population. Am. J. Respir. Crit. Care Med. 1999, 159:179-187.
35. Bjure J. Spirometric studies on normal subjects. IV. Ventilatory capacities in healthy children 7-17 years of age. Acta Paediatr. 1963, 52:232-240.
36. Berger K.I., Fagondes S.C., Giugliani R., Hardy K.A., Lee K.S., McArdle C., Scarpa M., Tobin M.J., Ward S.A., Rapoport D.M. Respiratory and sleep disorders in mucopolysaccharidosis. J. Inherit. Metab. Dis. 2013, 36:201-210.